Gilead Sciences has reported positive topline results from two Phase III studies, FISSION and NEUTRINO, of sofosbuvir conducted in patients infected with hepatitis C virus (HCV) and who were new to the treatment.
Sustained virologic response (SVR) rates were achieved and primary endpoints were met in both studies.
Go deeper with GlobalData
A 12-week course of the once-daily nucleotide sofosbuvir plus ribavirin (RBV) was evaluated in FISSION study whereas sofosbuvir in combination with RBV and pegylated interferon (peg-IFN) was assessed in NEUTRINO study.
Gilead Sciences chief scientific officer and research and development executive vice president Dr Norbert Bischofberger said the data supports the clinical profile of sofosbuvir as a potent, safe and well-tolerated treatment regimen effective across a range of HCV patient genotypes.
"The sofosbuvir regimens in these trials allowed us to shorten the duration of effective hepatitis C therapy to just 12 weeks for treatment-naïve patients with genotypes 1 through 6," Bischofberger said.
The 67% of patients in the FISSION achieved a SVR in the sofosbuvir plus RBV treatment group compared to 67% in the pegylated interferon alfa-2a (peg-IFN) plus RBV treatment group.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe FISSION study met its primary efficacy endpoint of non-inferiority of sofosbuvir plus RBV to peg-IFN plus RBV, demonstrating common adverse events such as fatigue, headache, nausea, insomnia and dizziness.
NEUTRINO study met its primary efficacy endpoint of superiority compared to a predefined historic control SVR rate of 60% with 90% of patients achieving SVR12 after completing therapy.
Fatigue, headache, nausea, insomnia and anemia were the most common adverse events that occurred in the NEUTRINO study.
Image: Electron micrographs of hepatitis C virus purified from cell culture. Scale bar is 50 nanometers. Photo: Courtesy of the Center for the Study of Hepatitis C, The Rockefeller University.
